AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12215757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran/Melagatran (highest dose)
Number of subjects: 4664
Study 12215757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran/Melagatran (24 mg, twice daily)
Number of subjects: 4664
Study 12215757 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (40 mg, once daily)
Number of subjects: 4664
Study 12215757 — intervention group
Group type: COMPARATOR
Intervention: Dalteparin (5000 IE, once daily)
Number of subjects: 4664
Study 12215757 — intervention group
Group type: EXPERIMENTAL
Intervention: Melagatran (3 mg, twice daily)
Number of subjects: 4664
Study 9579164 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular inhaled corticosteroids
Number of subjects: 50
Study 9579164 — intervention group
Group type: COMPARATOR
Intervention: Not receiving regular corticosteroids
Number of subjects: 50
Study 8563223 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA and IgG gliadin antibodies (AGA) and IgA endomysium antibodies (EMA) in coeliac disease (CD)
Number of subjects: 3783
Study 8563223 — intervention group
Group type: COMPARATOR
Intervention: EMA
Number of subjects: 3783
Study 8563223 — intervention group
Group type: COMPARATOR
Intervention: IgA AGA
Number of subjects: 3783
Study 8563223 — intervention group
Group type: COMPARATOR
Intervention: IgG AGA
Number of subjects: 3783
Study 8563223 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined determination of EMA and AGA
Number of subjects: 3783
Study 8563223 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD)
Number of subjects: 3783
Study 2096204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 2096204 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 21
Study 2096204 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial 24 h BP
Number of subjects: 21
Study 2096204 — intervention group
Group type: EXPERIMENTAL
Intervention: Waking hours
Number of subjects: 21
Study 2096204 — intervention group
Group type: EXPERIMENTAL
Intervention: White coat-induced BP increase
Number of subjects: 21
Study 2096204 — intervention group
Group type: EXPERIMENTAL
Intervention: Alarm reaction to physician presence
Number of subjects: 21
Study 657100 — intervention group
Group type: EXPERIMENTAL
Intervention: G.A.T.L.A. protocol (vincristine-prednisone plus surgery and/or radiotherapy, craniocervical radiotherapy, intrathecal methotrexate, anti-leukemia and anti-lymphoma treatments)
Number of subjects: 122
Study 657100 — intervention group
Group type: COMPARATOR
Intervention: No uniform treatment (1966-1972 group)
Number of subjects: 122
Study 31489024 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia combined with micro‐traumatic evacuation of cerebral hemorrhage
Number of subjects: 136
Study 31489024 — intervention group
Group type: COMPARATOR
Intervention: Micro‐traumatic evacuation of cerebral hemorrhage with conventional symptomatic treatment (Control)
Number of subjects: 136
Study 28694269 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and support
Number of subjects: 120
Study 28694269 — intervention group
Group type: COMPARATOR
Intervention: Financial reimbursement
Number of subjects: 120
Study 28694269 — intervention group
Group type: COMPARATOR
Intervention: Electronic brief advice
Number of subjects: 120
Study 25553336 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping strategies training program (6 sessions, 1.5 hours each)
Number of subjects: 87
Study 23386160 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic interval appendectomy
Number of subjects: 100
Study 23386160 — intervention group
Group type: COMPARATOR
Intervention: Open interval appendectomy
Number of subjects: 100
Study 21350041 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline with different modes of cessation counseling
Number of subjects: 1161
Study 19048594 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytology combined with hrHPV detection
Number of subjects: 210
Study 19048594 — intervention group
Group type: COMPARATOR
Intervention: Cytology alone
Number of subjects: 210
Study 19048594 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined testing strategy (cytology and hrHPV)
Number of subjects: 210
Study 19048594 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytology and hrHPV testing
Number of subjects: 210
Study 17874489 — intervention group
Group type: EXPERIMENTAL
Intervention: Coitus at least once weekly
Number of subjects: 76
Study 17874489 — intervention group
Group type: COMPARATOR
Intervention: No coitus
Number of subjects: 76
Study 15181067 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone, 400 mg/d (early intervention)
Number of subjects: 126
Study 15181067 — intervention group
Group type: COMPARATOR
Intervention: Placebo (late intervention)
Number of subjects: 126
Study 15181067 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (after developing diabetes)
Number of subjects: 126
Study 11747172 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-mounted JoStent
Number of subjects: 505
Study 11747172 — intervention group
Group type: COMPARATOR
Intervention: Premounted Multi-Link Duet stent
Number of subjects: 505
Study 9258733 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate cytologic evaluation (ICE)
Number of subjects: 80
Study 8334584 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmentally applied TENS
Number of subjects: 10
Study 8334584 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterosegmentally applied TENS
Number of subjects: 10
Study 8334584 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 10
Study 3706675 — intervention group
Group type: EXPERIMENTAL
Intervention: New inhalation technique (shrug of the shoulder method)
Number of subjects: 20
Study 3706675 — intervention group
Group type: COMPARATOR
Intervention: Conventional inhalation technique
Number of subjects: 20
Study 30498336 — intervention group
Group type: EXPERIMENTAL
Intervention: Cucumis sativus extract (CSE) 10 mg twice daily
Number of subjects: 122
Study 30498336 — intervention group
Group type: COMPARATOR
Intervention: Glucosamine-chondroitin (GC) 1,350 mg twice daily
Number of subjects: 122
Study 27213735 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/Ketamine (1:1)
Number of subjects: 100
Study 27213735 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/Ketamine (3:1)
Number of subjects: 100
Study 25219207 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal endoscope
Number of subjects: 66
Study 25219207 — intervention group
Group type: COMPARATOR
Intervention: Control (routine method of intraoral path)
Number of subjects: 66
Study 23730956 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichuris suis ova (TSO) 500
Number of subjects: 36
Study 23730956 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichuris suis ova (TSO) 7500
Number of subjects: 36
Study 23730956 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichuris suis ova (TSO) 2500
Number of subjects: 36
Study 23730956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 20965814 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity anticoagulant treatment with warfarin (INR maintained between 1.5 and 2.0)
Number of subjects: 845
Study 20965814 — intervention group
Group type: COMPARATOR
Intervention: Standard anticoagulant intensity with warfarin (INR maintained between 2.0 and 3.0)
Number of subjects: 845
Study 18981357 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history assessment
Number of subjects: 1342
Study 18981357 — intervention group
Group type: COMPARATOR
Intervention: Genetic test results
Number of subjects: 1342
Study 12081674 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycolic acid peels (20%)
Number of subjects: 10
Study 12081674 — intervention group
Group type: COMPARATOR
Intervention: Microdermabrasion (mild setting)
Number of subjects: 10
Study 9795298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 409
Study 9795298 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 409
Study 9795298 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid
Number of subjects: 409
Study 9795298 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 409
Study 7865650 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenolphthalein 30 mg
Number of subjects: 10
Study 7865650 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenolphthalein glucuronide equivalent to 30 mg phenolphthalein
Number of subjects: 10
Study 7865650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7865650 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenolphthalein (doses of 15, 30, 45, 60, 75, and 90 mg)
Number of subjects: 10
Study 7865650 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenolphthalein glucuronide (doses of 24, 48, 72, 96, 120, and 144 mg)
Number of subjects: 10
Study 2802557 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg) twice daily for 3 days
Number of subjects: 74
Study 2802557 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg) twice daily for 7 days
Number of subjects: 74
Study 2802557 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (300 mg) twice daily for 7 days
Number of subjects: 74
Study 2802557 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (160/800 mg) twice daily for 7 days
Number of subjects: 74
Study 2802557 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 74
Study 2802557 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 74
Study 2802557 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 74
Study 1096686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine therapy (200 mg daily)
Number of subjects: 76
Study 1096686 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine (50 mg and 100 mg)
Number of subjects: 76
Study 1096686 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 76
Study 31629372 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Zhiqiao Gancao (ZQGC) decoction
Number of subjects: 0
Study 31629372 — intervention group
Group type: COMPARATOR
Intervention: Bed rest
Number of subjects: 0
Study 31629372 — intervention group
Group type: COMPARATOR
Intervention: Oral anti-inflammatory drug celecoxib
Number of subjects: 0
Study 28243790 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar TURP
Number of subjects: 497
Study 28243790 — intervention group
Group type: COMPARATOR
Intervention: Monopolar TURP
Number of subjects: 497
Study 24151982 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-frequency breath (CFB) swimming
Number of subjects: 18
Study 24151982 — intervention group
Group type: COMPARATOR
Intervention: Stroke-matched (SM) condition
Number of subjects: 18
Study 23324098 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1940 (400 μg)
Number of subjects: 44
Study 23324098 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1940 (800 μg)
Number of subjects: 44
Study 23324098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 20971614 — intervention group
Group type: EXPERIMENTAL
Intervention: GH+Ox 0.03 mg/kg/d
Number of subjects: 133
Study 20971614 — intervention group
Group type: EXPERIMENTAL
Intervention: GH+Ox 0.06 mg/kg/d
Number of subjects: 133
Study 20971614 — intervention group
Group type: COMPARATOR
Intervention: GH+Pl (placebo)
Number of subjects: 133
Study 19935025 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal treatment starting around 20 weeks of gestation (n=542)
Number of subjects: 1000
Study 19935025 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving no treatment until 6 weeks after pregnancy (n=540)
Number of subjects: 1000
Study 19935025 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1000
Study 19935025 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal treatment
Number of subjects: 1000
Study 16908486 — intervention group
Group type: EXPERIMENTAL
Intervention: TGN1412 (anti-CD28 monoclonal antibody)
Number of subjects: 6
Study 15114598 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic transfusion therapy
Number of subjects: 61
Study 15114598 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic SCD patients
Number of subjects: 61
Study 15114598 — intervention group
Group type: EXPERIMENTAL
Intervention: ACS
Number of subjects: 61
Study 15114598 — intervention group
Group type: EXPERIMENTAL
Intervention: APE
Number of subjects: 61
Study 11710402 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (Cr) 20 g for 5 days
Number of subjects: 23
Study 11710402 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 23
Study 9020286 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin acetate-flutamide combination
Number of subjects: 45000
Study 9020286 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy
Number of subjects: 45000
Study 9020286 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium-89
Number of subjects: 45000
Study 9020286 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol (DES)
Number of subjects: 45000
Study 9020286 — intervention group
Group type: EXPERIMENTAL
Intervention: Total androgen blockade (TAB)
Number of subjects: 45000
Study 7970852 — intervention group
Group type: EXPERIMENTAL
Intervention: LoFric catheter
Number of subjects: 31
Study 7970852 — intervention group
Group type: COMPARATOR
Intervention: PVC catheter
Number of subjects: 31
Study 3297732 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril therapy for 2 weeks
Number of subjects: 10
Study 3297732 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 10
Study 30829206 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrus communis fruit extract loaded emulgel (5% w/w)
Number of subjects: 13
Study 30829206 — intervention group
Group type: COMPARATOR
Intervention: Placebo (without fruit extract)
Number of subjects: 13
Study 29245259 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudendal nerve block
Number of subjects: 175
Study 29245259 — intervention group
Group type: COMPARATOR
Intervention: Control (general anesthesia only)
Number of subjects: 175
Study 26283229 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text reminders for adherence to artemether-lumefantrine and post-treatment review
Number of subjects: 20
Study 26283229 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated SMS distribution system
Number of subjects: 20
Study 23507773 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 IU of intranasal insulin
Number of subjects: 104
Study 23507773 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 IU of intranasal insulin
Number of subjects: 104
Study 23507773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 23507773 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (both doses)
Number of subjects: 104
Study 21554245 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic absolute exercise (H-AE)
Number of subjects: 60
Study 21554245 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic relative exercise (H-RE)
Number of subjects: 60
Study 21554245 — intervention group
Group type: COMPARATOR
Intervention: Normoxic control (N-C)
Number of subjects: 60
Study 21554245 — intervention group
Group type: COMPARATOR
Intervention: Hypoxic control (H-C)
Number of subjects: 60
Study 21554245 — intervention group
Group type: COMPARATOR
Intervention: Normoxic exercise (N-E)
Number of subjects: 60
Study 19289933 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 16899712 — intervention group
Group type: EXPERIMENTAL
Intervention: 240-kcal liquid meals
Number of subjects: 9
Study 16899712 — intervention group
Group type: EXPERIMENTAL
Intervention: 240-kcal solid meals
Number of subjects: 9
Study 16899712 — intervention group
Group type: COMPARATOR
Intervention: Water (240 ml)
Number of subjects: 9
Study 15816266 — intervention group
Group type: EXPERIMENTAL
Intervention: ADA questionnaire for major diabetes risk factors
Number of subjects: 317
Study 15816266 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting capillary blood glucose
Number of subjects: 317
Study 15816266 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI) >25 kg/m2
Number of subjects: 317
Study 15816266 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist/hip ratio
Number of subjects: 317
Study 15816266 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall risk assessment
Number of subjects: 317
Study 12575585 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with Chinese herbal medicine (Spleen‐Kidney tonifying)
Number of subjects: 101
Study 12575585 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 101
Study 9040055 — intervention group
Group type: EXPERIMENTAL
Intervention: MCAF/MCP-1 in myocardial infarction at 3 hours (133 +/- 19 pg/ml)
Number of subjects: 41
Study 9040055 — intervention group
Group type: EXPERIMENTAL
Intervention: MCAF/MCP-1 in myocardial infarction at 9 hours (143 +/- 20 pg/ml)
Number of subjects: 41
Study 9040055 — intervention group
Group type: EXPERIMENTAL
Intervention: MCAF/MCP-1 in myocardial infarction at 24 hours (168 +/- 13 pg/ml)
Number of subjects: 41
Study 9040055 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of MCAF/MCP-1 with IL-8 at 12 hours
Number of subjects: 41
Study 7954745 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint oil and ethanol
Number of subjects: 32
Study 7954745 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint oil, eucalyptus oil, and ethanol
Number of subjects: 32
Study 7954745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 3309198 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate (IT MTX) as prophylaxis
Number of subjects: 100
Study 3309198 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy as prophylaxis
Number of subjects: 100
Study 3309198 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS relapse
Number of subjects: 100
Study 3309198 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated CNS relapse
Number of subjects: 100
Study 3309198 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple CNS relapses
Number of subjects: 100
Study 27853872 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosomatic treatment for the elderly (5-week therapy)
Number of subjects: 116
Study 27853872 — intervention group
Group type: COMPARATOR
Intervention: Waiting time (5-week control condition)
Number of subjects: 116
Study 27632917 — intervention group
Group type: EXPERIMENTAL
Intervention: High MUFA:SFA ratio ground beef (HR = 1.1)
Number of subjects: 13
Study 27632917 — intervention group
Group type: COMPARATOR
Intervention: Low MUFA:SFA ratio ground beef (LR = 0.71)
Number of subjects: 13
Study 27632917 — intervention group
Group type: COMPARATOR
Intervention: Self-selected washout diet (SS)
Number of subjects: 13
Study 24477298 — intervention group
Group type: EXPERIMENTAL
Intervention: EVEN protein distribution (31.5 ± 1.3 g at breakfast, 29.9 ± 1.6 g at lunch, 32.7 ± 1.6 g at dinner)
Number of subjects: 8
Study 24477298 — intervention group
Group type: COMPARATOR
Intervention: SKEW protein distribution (10.7 ± 0.8 g at breakfast, 16.0 ± 0.5 g at lunch, 63.4 ± 3.7 g at dinner)
Number of subjects: 8
Study 22704410 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba leaf tablets, 19.2 mg each dose, taken 3 times a day for 6 months
Number of subjects: 120
Study 22704410 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 120
Study 20728068 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold application
Number of subjects: 90
Study 20728068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 20728068 — intervention group
Group type: COMPARATOR
Intervention: Control (standard analgesic administration)
Number of subjects: 90
Study 18462573 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs + Cognitive Behaviour Therapy (CBT)
Number of subjects: 208
Study 18462573 — intervention group
Group type: COMPARATOR
Intervention: SSRIs only
Number of subjects: 208
Study 18462573 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs + CBT
Number of subjects: 208
Study 16188920 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg)
Number of subjects: 30
Study 16188920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 14733799 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible bronchoscopy
Number of subjects: 125
Study 14733799 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 125
Study 10921167 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined method of acupuncture with pressure on otopoints
Number of subjects: 86
Study 10921167 — intervention group
Group type: COMPARATOR
Intervention: Simple acupuncture
Number of subjects: 86
Study 10921167 — intervention group
Group type: COMPARATOR
Intervention: Simple pressure on otopoints
Number of subjects: 86
Study 8832448 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.1 mg/kg
Number of subjects: 144
Study 8832448 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine 1 mg/kg
Number of subjects: 144
Study 8832448 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium 0.6 mg/kg, Atracurium 0.5 mg/kg, Succinylcholine 1 mg/kg
Number of subjects: 144
Study 1417430 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 198
Study 1417430 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal therapy
Number of subjects: 198
Study 1417430 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride plus clinical management (CM)
Number of subjects: 198
Study 1417430 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo plus clinical management (CM)
Number of subjects: 198
Study 6701786 — intervention group
Group type: EXPERIMENTAL
Intervention: Hickman catheter (HC)
Number of subjects: 0
Study 6701786 — intervention group
Group type: COMPARATOR
Intervention: Polyvinylchloride central venous catheters (CVC)
Number of subjects: 0
Study 6701786 — intervention group
Group type: EXPERIMENTAL
Intervention: Hickman catheter (HC) (non-randomized group)
Number of subjects: 0
Study 30611960 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose baclofen (30–270 mg/d)
Number of subjects: 0
Study 30611960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0